December 1, 2023 10:46 AM EST

Tharimmune's public offering; Culmination Bio raises $10M; Pepper Bio's seed round led by NFX

Jaimy Lee

Deputy Editor

Tharimmune closes $11M in public offering: The company, which is developing therapies that aim to treat rare, inflammatory, and oncologic conditions,

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Tharimmune's public offering; Culmination Bio raises $10M; Pepper Bio's seed round led by NFX

Jaimy Lee

Deputy Editor

Sign up to read this article for free.

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Tharim­mune's pub­lic of­fer­ing; Cul­mi­na­tion Bio rais­es $10M; Pep­per Bio's seed round led by NFX

Jaimy Lee

Deputy Editor

Sign up to read this article for free.

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

Tharimmune's public offering; Culmination Bio raises $10M; Pepper Bio's seed round led by NFX

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?